北京大學

王學清 博士，副教授，碩士研究生導師

電話：010-82801584,

電子信箱：wangxq@bjmu.edu.cn

1989.9-1993.7 北京醫(yī)科大學藥學專業(yè)學習，獲學士學位。2001.9-2003.7年于北京大學藥劑學專業(yè)在職學習，獲碩士學位。2005.9-2008.7年于中國科學院生物物理研究所在職學習，獲博士學位。2011年于奧地利因斯布魯克大學進修學習三個月。1993.8留校后進入北京醫(yī)科大學藥學院藥劑教研室從事教學和科研工作，主要承擔本科生、研究生的藥劑學、生物藥劑學與藥物動力學的理論課程與實驗課程的教學工作。1998年聘為講師，2009年聘為副教授。參與多項國家課題和新藥制劑開發(fā)工作，如NSF重點資助項目“基于分子靶向給藥的腫瘤聯(lián)合治療”（在研）、973計劃資助項目“納米技術改善難溶性藥物功效的應用基礎研究” （在研）、科技部“重大新藥創(chuàng)制”新制劑與新釋藥系統(tǒng)技術平臺建設項目（在研）、863計劃資助項目“環(huán)孢素A納米粒口服劑型的研究”（已結題）、NSF重點資助項目“載體給藥系統(tǒng)的分子藥劑學” （已結題）、“蚯蚓纖連蛋白酶在乙型肝炎治療中的基礎研究”、一類新藥“RS-27 輸液劑的研制”等。

主要研究方向

納米技術增加難溶性藥物及多肽蛋白類藥物的口服吸收，腫瘤靶向納米藥物輸送系統(tǒng)研究。
 
代表性論文

1. Xue-qing Wang, Jie-ming Fan, Ya-ou Liu, Bo Zhao, Zeng-rong Jia, Qiang Zhang*. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. International Journal of Pharmaceutics. 2011, 419: 339-346.

2. Ya-Ou Liu, Jie-Ming Fan, Xue-Qing Wang*, Qiang Zhang. Preparation of sorafenib selfmicroemulsifying drug delivery system and its relative bioavailability in rats. Journal of Chinese Pharmaceutical Sciences. 2011, 20:164-170.

3. Wang Xueqing, Zhang Yuan, Pan Rong, He Rongqiao, Distribution of earthworm fibrinolytic enzyme in rat gastrointestinal tract after oral administration. Chinese Journal of New Drugs. 2010, 19: 1360-1364.

4. Xue-Qing Wang, Lan Chen, Rong Pan, Jing Zhao, Ying Liu, Rong-Qiao He, An earthworm protease cleaving serum fibronectin and decreasing HBeAg in HepG2.2.15 cells. BMC biochemistry. 2008, 9:30 doi:10.1186/1471-2091-9-30

5. Xue-Qing Wang, Jun-Dong Dai, Hua Zhang, Xuan Zhang,Jian-Cheng Wang, Qiang Zhang*. Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats. Journal of Nanoscience and Nanotechnology. 2008, 8:2422-2431.

6. Xue-qing Wang, Jia Huang, Jun-dong Dai, Tao Zhang, Wan-liang Lu,Hua Zhang, Xuan Zhang, Jian-cheng Wang, Qiang Zhang*. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. International Journal of Pharmaceutics，2006,322:146 -153.

7. Xue-qing Wang, Jun-dong Dai, Zhen Chen, Tao Zhang, Gui-min Xia, Qiang Zhang*. Bioavailability and Pharmacokinetics of Cyclosporine A loaded pH-sensitive nanoparticles for oral administration. Journal of Controlled Release, 2004, 97: 421-429.

8. Jun-dong Dai, Tsuneji Nagai, Xue-qing Wang, Tao Zhang, Meng Meng, Qiang Zhang*. pH-sensitive nanoparticles for improving the oral bioavailability of Cyclosporine A. International Journal of Pharmaceutics, 2004,280: 229 -240.

9.Yuan Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*. Octreotide-Modified Polymeric Micelles as Potential Carriers for Targeted Docetaxel Delivery to Somatostatin Receptor Overexpressing Tumor Cells. Pharm Res. 2011, 28: 1167-1178.

10. Yu Xiang, Liang Liang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. Journal of Controlled Release. 2011,152: 402-410.

11. Zengrong Jia, Ping Lin, Yu Xiang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. European Journal of Pharmaceutics and Biopharmaceutics . 2011, 79: 126-134.

12. Junlin Zhang, Wu Jin, Xueqing Wang, Jiancheng Wang, Xuan Zhang and Qiang Zhang*. A Novel Octreotide Modified Lipid Vesicle Improved the Anticancer Efficacy of Doxorubicin in Somatostatin Receptor 2 Positive Tumor Models. Mol Pharm. 2010, 7:1159-68。

13.  Wu CS, Wang XQ, Meng M, Li MG, Zhang H, Zhang X, Wang JC, Wu T, Nie WH, Zhang Q*. Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats. J Microencapsul. 2010, 27:205-217.

14. Wenbing Dai, Tingyuan Yang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. Journal of Drug Targeting. 2009 (doi:10.3109/ 10611860903353354)。